Dheemant (Abhi) Attada

What is the current state of epi-drugs targeting DNA methylation used against leukemias, and what is their validity in terms of efficacy and safety?

Started Apr. 14, 2023

Abstract or project description

Epigenetic modifications are alterations to the genome that do not change the nucleotide sequence. These changes can alter gene expression, and have emerged as crucial factors in the onset and progression of various cancers, prompting increased research efforts to understand their role in disease pathogenesis. Here, we explore the efficacy and safety of emerging epigenetic treatments, or epi-drugs, as a new avenue for treating various leukemias. Specifically, we examine the role of DNA methylation in regulating gene expression patterns and cellular behavior, evaluate a series of clinical trials performed on the most common epi-drugs for cancer treatment, including 5-Azacytidine and Decitabine, and introduce strategies that may enhance the effectiveness of these agents, including combination therapies and personalized treatment approaches. Furthermore, emerging trends and technologies in epi-drug research are discussed, highlighting the potential for advancements in the field, with a particular focus on DNA methylation-targeting epi-drugs. Further research into epidrugs, epigenetic treatments, and combination therapies holds the potential to substantially reduce the burden on leukemia patients, offering new hope for improved treatment outcomes.